Shots:

• The NMPA has accepted the marketing authorization application for BAT1806, a biosimilar of Roche’s Actemra (tocilizumab) for the treatment of patients with arthritis
• In June 2021, the results from the P-III study of BAT1806 showed equivalent efficacy and comparable safety to the originator in patients with moderate-to-severe RA
• Tocilizumab is an immunosuppressive drug that acts on the receptor of the inflammatory cytokine receptor, IL-6 & is used for the treatment of inflammatory conditions including RA and systemic JIA. In June' 2021, the US FDA has granted a EUA for the treatment of COVID-19 in the US & is sold under the brand name Actemra

Ref: Businesswire | Image: Bio-Thera